| Date | Title | Description |
| 03.02.2025 | Enduro Genetics raises $12m Series A to turbocharge biomanufacturing | Enduro Genetics—a Danish startup on a mission to slash the cost of biomanufacturing by “addicting” cells to high production—has raised €12 million ($12.4 million) in Series A funding from Supernova Invest, NOON Ventures, and Sandwater.
The ... |
| 05.06.2024 | Biomanufacturing game-changer? Enduro Genetics unveils elegant solution to declining cell productivity | In any bioreactor, over time, only a certain percentage of cells actually produce what they have been engineered to express, says Enduro Genetics CEO Christian Munch. The rest are essentially freeloaders, consuming valuable feedstocks witho... |
| 20.05.2024 | SynBioBeta 2024: From novel hosts to ‘tricking’ cells to be more productive… addressing the ‘scale-cost paradox’ in biomanufacturing | Since insulin produced by genetically engineered bacteria—rather than the pancreases of slaughtered animals—was first approved in 1982, the market for ‘biomanufactured’ products produced by microbial, animal, or plant cells has grown rapidl... |
| 13.03.2024 | Global gRNA Research Analysis Report 2024: Precision in Gene Editing and Rising Adoption of NGS Technologies Enhancing gRNA Applications | - |
| 26.09.2023 | Revvity expands access to base editing technology with aim to accelerate discovery to cure | Launch of Pin-pointTM base editing reagents improves access to new-generation editing technology
Access to the Pin-point system now bridges discovery, preclinical and clinical with the same technology platform
Reagent launch puts clinically... |
| 15.06.2022 | YCharOS adds Developmental Studies Hybridoma Bank (DSHB) to Industry Advisory Committee | YCharOS continues to expand Industry Advisory Committee and releases new open data
Adding an academic partner shows the strength and flexibility of YCharOS’ open science framework.”
— Dr. Aled EdwardsTORONTO, CANADA, June 15, 2022 /EINPress... |
| 21.03.2022 | YCharOS adds ABclonal Technology to Industry Advisory Committee | YCharOS continues to expand Industry Advisory Committee and releases new open data TORONTO, CANADA, March 21, 2022 /EINPresswire.com/ -- YCharOS Inc., an open science company with the mission of characterizing commercially available antibod... |
| 03.02.2022 | PerkinElmer : to Showcase Expanded Life Science / Cell & Gene Therapy Portfolios and Automated Genomic Workflows at SLAS 2022 | PDF Version
End-to-end solutions designed to help scientists streamline and improve
drug discovery R&D productivity
WHAT: PerkinElmer, Inc., a global leader committed to innovating for a healthier world, is at SLAS 2022 on February 7-9 ... |
| 07.10.2021 | PerkinElmer’s Horizon Discovery CHOSOURCE platform expands | Existing CHO platform, featuring low cost and no royalty or licence tie-ins, expands with new cell line to help develop biotherapeutics with increased potency and longevity and decreased side effects.
WALTHAM, Mass.-- PerkinElmer Inc., a gl... |
| 07.10.2021 | PerkinElmer’s Horizon Discovery CHOSOURCE platform expands | PerkinElmer’s Horizon Discovery CHOSOURCE platform expands
07-10-2021
Existing CHO platform, featuring low cost and no royalty or licence tie-ins, expands with new cell line to help develop biotherapeutics with increased potency and longevi... |
| 11.05.2021 | Appia Bio Comes Out of Stealth Aiming to Offer Faster, Safer Cancer-Fighting Therapies | Cell therapy has taken the oncology world by storm.
For cancer patients who have tried every other treatment, cell therapies not only have the potential to kill cancer cells in the moment, but they can multiply and continue bolstering the i... |
| 30.03.2021 | Horizon Discovery extends gene modulation portfolio | Horizon Discovery extends gene modulation portfolio
30-03-2021
CRISPRi innovations provide expanded experimental options and flexibility for researchers, facilitating disease and drug research.
Horizon Discovery, a PerkinElmer, Inc. (NYSE:P... |
| 30.03.2021 | Horizon Discovery extends gene modulation portfolio | CRISPRi innovations provide expanded experimental options and flexibility for researchers, facilitating disease and drug research.
Horizon Discovery, a PerkinElmer, Inc. (NYSE:PKI) company, announced that its gene editing and modulation por... |
| 02.11.2020 | PerkinElmer to acquire cell engineering company Horizon Discovery for £296m ($383m) | PerkinElmer to acquire cell engineering company Horizon Discovery for £296m ($383m)
02-11-2020
PerkinElmer, Inc. and Cambridge based Horizon Discovery Group plc are pleased to announce that they have reached an agreement on the terms of a r... |
| 30.04.2020 | Horizon Discovery extends coverage of OncoSpan reference standards to FFPE and Liquid Biopsy | Horizon Discovery extends coverage of OncoSpan reference standards to FFPE and Liquid Biopsy
30-04-2020
Horizon Discovery Group plc (LSE: HZD), a global leader in the application of gene editing and gene modulation for cell line engineering... |
| 30.04.2020 | Horizon Discovery extends coverage of OncoSpan reference standards to FFPE and Liquid Biopsy | Horizon Discovery Group plc (LSE: HZD), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced it has added two new sample formats to its cell-based OncoSpan reference standards for... |
| 14.04.2020 | Horizon Discovery offers CHOSOURCE™ platform for COVID-19-related therapeutics and diagnostics | Horizon Discovery offers CHOSOURCE™ platform for COVID-19-related therapeutics and diagnostics
14-04-2020
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, today a... |
| 06.04.2020 | Horizon Discovery expands cell-based CRISPR screening services | Horizon Discovery expands cell-based CRISPR screening services
06-04-2020
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the addition of an arra... |
| 06.04.2020 | Horizon Discovery expands cell-based CRISPR screening services | Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the addition of an arrayed CRISPR knockout screening service for primary human B cells to its cel... |
| 30.01.2020 | Mammoth Biosciences aims to be Illumina for the gene editing generation | In 1998, the startup company Illumina launched a revolution in the life sciences industry by developing technology to slash the costs of identifying and mapping genetic material.
Now, a little over 20 years later, Mammoth Biosciences is hop... |
| 30.01.2020 | Mammoth Biosciences raises $45M to expand into therapeutics | The company, which uses CRISPR technology to diagnose diseases, will being treating disease as well
By now most of us have at least heard of CRISPR, but maybe we don't know what exactly it is. CRISPR, essentially, is a tool that make it eas... |
| 28.10.2019 | Horizon Discovery reaches integration milestone and launches new website | Horizon Discovery Group plc (LSE: HZD), a global leader in the application of gene editing and gene modulation for cell line engineering, today went live with a new website and ecommerce system, marking a significant milestone in the Compan... |
| 28.10.2019 | Horizon Discovery reaches integration milestone and launches new website | Horizon Discovery reaches integration milestone and launches new website
28-10-2019
Horizon Discovery Group plc (LSE: HZD), a global leader in the application of gene editing and gene modulation for cell line engineering, today went live wi... |
| 30.09.2019 | Horizon Discovery signs licence agreement with Glenmark Pharmaceuticals for GS knockout CHO cell line for manufacture of biotherapeutics | Horizon Discovery signs licence agreement with Glenmark Pharmaceuticals for GS knockout CHO cell line for manufacture of biotherapeutics
30-09-2019
Horizon Discovery Group plc, a global leader in the application of gene editing and gene mod... |
| 24.09.2018 | Horizon Discovery Myeloid DNA Reference Standard supports genetic testing of leukemia | Horizon Discovery Myeloid DNA Reference Standard supports genetic testing of leukemia
24-09-2018
Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Re... |
| 14.09.2018 | Horizon Discovery Edit-R crRNA libraries adopted by AstraZeneca | Horizon Discovery Edit-R crRNA libraries adopted by AstraZeneca
14-09-2018
Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announces AstraZeneca has adopted its Edit-R™ crRNA libraries as... |
| 12.04.2018 | Horizon and Pirbright Institute support research into improvement of vaccine yields | Horizon and Pirbright Institute support research into improvement of vaccine yields
12-04-2018
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation to deliver inspired cell solutions, today ann... |
| 27.09.2017 | Horizon Discovery Group delivers consistent strong growth | Horizon Discovery Group delivers consistent strong growth
27-09-2017
Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, is positioned for additional scale following its transformational acquisitio... |
| 01.08.2017 | Horizon Discovery releases CHO genome sequence to drive innovation in bioproduction | Horizon Discovery releases CHO genome sequence to drive innovation in bioproduction
01-08-2017
Horizon Discovery, a global leader in the application of gene editing technologies, today announced it has released a complete, high-quality, wel... |
| 19.07.2017 | Horizon Discovery Group plc acquires GE Healthcare Dharmacon, Inc. for $85 million | Horizon Discovery Group plc acquires GE Healthcare Dharmacon, Inc. for $85 million
19-07-2017
Horizon Discovery Group plc (LSE: HZD), a global leader in the application of gene editing technologies, today announces that it has entered into ... |
| 17.07.2017 | Sphere Fluidics and partners win InnovateUK grant to develop the world’s first desktop genome | Sphere Fluidics and partners win InnovateUK grant to develop the world’s first desktop genome
17-07-2017
Sphere Fluidics Limited and its partners have just won a £1 million grant to develop a novel automated single cell genome engineering p... |
| 08.03.2017 | Horizon Discovery partners with Amplycell SA for bioproduction cell line optimisation | Horizon Discovery partners with Amplycell SA for bioproduction cell line optimisation
08-03-2017
Horizon Discovery Group plc, the world leader in the application of gene editing technologies, including the provision of bioproduction cell li... |
| 14.02.2017 | Horizon Discovery signs a Master Service Agreement with a top three pharmaceutical company | Horizon Discovery signs a Master Service Agreement with a top three pharmaceutical company
14-02-2017
Horizon Discovery today announces the signing of a Master Services Agreement (MSA) with a top three global pharmaceutical company extendin... |
| 19.10.2016 | Horizon Discovery signs licensing agreement for biomanufacturing cell lines | Horizon Discovery signs licensing agreement for biomanufacturing cell lines
19-10-2016
Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today announces a new licensing agreement with an unnamed ... |
| 06.09.2016 | Horizon Discovery and Fulcrum Therapeutics collaborate for novel target discovery | Horizon Discovery and Fulcrum Therapeutics collaborate for novel target discovery
06-09-2016
Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today announced a new collaboration with Fulcrum The... |
| 01.09.2016 | Horizon Discovery Group and Ventana Medical Systems sign agreement for reference standards | Horizon Discovery Group and Ventana Medical Systems sign agreement for reference standards
01-09-2016
The Agreement covers the development, manufacture and commercialisation of cell line derivative materials for use as IHC Reference Standar... |
| 02.03.2016 | Horizon Discovery Group forms joint venture with Centauri Therapeutics Limited | Horizon Discovery Group forms joint venture with Centauri Therapeutics Limited
02-03-2016
Horizon Discovery Group plc, the leading international gene editing company, announces today that it has formed an immuno-oncology joint venture, Avvi... |
| 22.07.2015 | Horizon Discovery Group plc publishes trading update | Horizon Discovery Group plc publishes trading update
22-07-2015
Horizon Discovery Group plc, the international life science group supplying research tools and services that power genomics research and the development of personalised medicin... |
| 17.06.2015 | Preparing for AIM listing? Maximise your company’s value | Marketing is often considered an afterthought for science and technology companies preparing for an IPO, but according to Simon Fryer, CEO at KISS, sorting out a company’s brand proposition, marketing collateral and profile will help achiev... |
| 17.06.2015 | Preparing for AIM listing? Maximise your company’s value | Preparing for AIM listing? Maximise your company’s value
17-06-2015
Marketing is often considered an afterthought for science and technology companies preparing for an IPO, but according to Simon Fryer, CEO at KISS, sorting out a company’s ... |
| 14.04.2015 | Horizon reports strong maiden full year results since listing on AIM | Horizon reports strong maiden full year results since listing on AIM
14-04-2015
Horizon Discovery Group plc, the international life science company providing research tools and services that power genomics research and the development of pe... |
| 23.03.2015 | Horizon Discovery Group plc and ArcherDX sign OEM agreement | Horizon Discovery Group plc and ArcherDX sign OEM agreement
23-03-2015
Horizon’s Reference Materials have been chosen by ArcherDX to validate its FusionPlex test for non-small cell lung cancer markers.
Cambridge, UK, and Boulder, CO, USA, 2... |
| 11.03.2015 | Horizon Discovery Group plc supports Cancer Research UK’s Stratified Medicine Programme | Horizon Discovery Group plc supports Cancer Research UK’s Stratified Medicine Programme
11-03-2015
Horizon Discovery Group plc, a leading provider of research tools to support translational genomics and the development of personalised medic... |
| 18.02.2015 | Horizon Discovery Group part of consortium awarded £1.67m Innovate UK funding | Horizon Discovery Group part of consortium awarded £1.67m Innovate UK funding
18-02-2015
Horizon Discovery Group plc, in a consortium with Centre for Process Innovation and the University of Manchester, is to receive £1.67 million funding t... |
| 02.02.2015 | Horizon selected as core facility by Tri-Institutional Therapeutics Discovery Institute | Horizon selected as core facility by Tri-Institutional Therapeutics Discovery Institute
02-02-2015
Horizon Discovery, the international life science company supplying research tools and services to organisations engaged in genomics research... |
| 29.01.2015 | Horizon Discovery CEO Darrin Disley wins 'Entrepreneur of the Year' award | Horizon Discovery CEO Darrin Disley wins 'Entrepreneur of the Year' award
29-01-2015
Horizon Discovery Group plc, the international life science company supplying research tools and services to organisations engaged in genomics research and... |
| 19.01.2015 | Horizon Discovery Group plc trading update shows continuing growth | Horizon Discovery Group plc trading update shows continuing growth
19-01-2015
Revenues for Horizon Discovery Group plc are expected to be ahead of consensus by approximately 7%, driven by an increased global demand for its expanded product,... |
| 08.01.2015 | Horizon Discovery Group plc acquires Haplogen Genomics GmbH | Horizon Discovery Group plc acquires Haplogen Genomics GmbH
08-01-2015
Strategic acquisition of high-throughput functional genomics platform aims to drive product development, revenue growth and enable broader market penetration.
Horizon Di... |
| 08.12.2014 | Horizon launches gene-engineered bioproduction cell line with flexible licensing model | Horizon's precisely engineered cell line will facilitate a new revenue stream and enable faster, more efficient production of therapeutic antibodies.
Horizon Discovery Group plc, a leading provider of research tools to support translational... |
| 08.12.2014 | Horizon launches gene-engineered bioproduction cell line with flexible licensing model | Horizon launches gene-engineered bioproduction cell line with flexible licensing model
08-12-2014
Horizon's precisely engineered cell line will facilitate a new revenue stream and enable faster, more efficient production of therapeutic anti... |
| 04.12.2014 | Horizon Discovery CEO Darrin Disley wins Executive of the Year award at SCRIP Awards 2014 | Horizon Discovery CEO Darrin Disley wins Executive of the Year award at SCRIP Awards 2014
04-12-2014
Dr Darrin Disley, the Chief Executive Officer of Horizon Discovery Group plc, a leading provider of research tools to support translational... |
| 24.11.2014 | Horizon Discovery Group plc and Adarza BioSystems enter supply & licensing agreement | Horizon Discovery Group plc and Adarza BioSystems enter supply & licensing agreement
24-11-2014
Agreement gives Horizon exclusive right to supply services on Adarza’s multiplex label-free immunoassay technology.
Cambridge, UK, and St. L... |
| 17.11.2014 | Horizon Discovery Group signs agreement with top pharma company for approximately $750,000 | Horizon Discovery Group signs agreement with top pharma company for approximately $750,000
17-11-2014
Horizon Discovery Group plc, a leading provider of research tools to support translational genomics and the development of personalized me... |
| 03.11.2014 | Horizon Discovery Group plc appoints Dr David Smoller as an Executive Director | Horizon Discovery Group plc appoints Dr David Smoller as an Executive Director
03-11-2014
Horizon Discovery Group plc, a leading provider of research tools to support translational genomics and the development of personalized medicines, tod... |
| 23.10.2014 | Horizon launches collection of Patient-Derived Xenograft models of breast cancer | Horizon launches collection of Patient-Derived Xenograft models of breast cancer
23-10-2014
Horizon Discovery Group plc, a leading provider of products, services and technologies in the field of genome engineering, today announced the launc... |
| 23.10.2014 | Horizon launches collection of Patient-Derived Xenograft models of breast cancer | Horizon Discovery Group plc, a leading provider of products, services and technologies in the field of genome engineering, today announced the launch of its Patient-Derived Xenograft (PDX) models of breast cancer under its SAGE Labs brand. ... |
| 29.09.2014 | Horizon Discovery Group plc acquires Sage Labs Inc. for $48M (£29M) | Horizon Discovery Group plc acquires Sage Labs Inc. for $48M (£29M)
29-09-2014
Horizon Discovery Group plc, the international life science company supplying research tools and services to organizations engaged in genomics research and the d... |
| 23.09.2014 | Horizon Discovery reports a strong first half, positioning for continued growth | Horizon Discovery reports a strong first half, positioning for continued growth
23-09-2014
Horizon Discovery Group plc (LSE: HZD), the international life science company supplying research tools to organisations engaged in genomics research... |
| 31.08.2014 | Horizon Discovery Group plc Acquires Sage Labs Inc. for $48M (£29M) | Acquisition makes Horizon the world’s leading gene-editing and translational genomics company
Cambridge, UK and St. Louis, MO, USA—September 29, 2014—Horizon Discovery Group plc (LSE: HZD) (“Horizon” or the “Company”), the international li... |
| 14.08.2014 | KISS team cycles from London to Cambridge, raising over £900 for Breakthrough Breast Cancer | On Sunday 27th July, a 12-strong team from KISS Communications, a leading Cambridge creative agency, undertook the gruelling 60 mile London to Cambridge cycle challenge in a bid to raise money for Breakthrough Breast Cancer, a worthy charit... |
| 14.08.2014 | KISS team cycles from London to Cambridge, raising over £900 for Breakthrough Breast Cancer | KISS team cycles from London to Cambridge, raising over £900 for Breakthrough Breast Cancer
14-08-2014
On Sunday 27th July, a 12-strong team from KISS Communications, a leading Cambridge creative agency, undertook the gruelling 60 mile Lond... |
| 05.08.2014 | Horizon Discovery adds three eminent CRISPR experts to its Scientific Advisory Board | Horizon Discovery adds three eminent CRISPR experts to its Scientific Advisory Board
05-08-2014
Horizon Discovery Group plc, the international life science company supplying research tools to organisations engaged in genomics research and t... |
| 23.07.2014 | Horizon Discovery reports strong performance | Horizon Discovery reports strong performance
23-07-2014
Horizon Discovery Group plc, the international life science company supplying research tools and services to organizations engaged in genomics research and the development of personali... |
| 19.06.2014 | KISS helps prepare pupils for the world of work | KISS helps prepare pupils for the world of work
19-06-2014
Cambridge Area 14-19 Partnership (CAP) has turned to KISS PR to help raise awareness of the need for more support from Cambridgeshire businesses to help make a difference to the reg... |
| 16.06.2014 | Horizon Discovery and LGC awarded grant for next generation cancer diagnostics | Horizon Discovery and LGC awarded grant for next generation cancer diagnostics
16-06-2014
Improving minimally invasive circulating DNA diagnostic assays supports implementation of stratified and personalized intervention strategies.
Horizon... |
| 12.06.2014 | Horizon Discovery licenses CRISPR gene editing technology from the Broad Institute | Horizon Discovery licenses CRISPR gene editing technology from the Broad Institute
12-06-2014
Horizon Discovery™ Group plc, the international life science company supplying research tools to organizations engaged in genomics research and th... |
| 11.06.2014 | KISS PR partners with Cambridge Roar | KISS PR partners with Cambridge Roar
11-06-2014
KISS PR has been appointed by The Cambridge Roar to handle a highly focused consumer and business PR campaign, to promote a series of charitable events which take place next month (July 2014).... |
| 09.06.2014 | Horizon Discovery strengthens Board with appointment of Non-Executive Directors | Horizon Discovery strengthens Board with appointment of Non-Executive Directors
09-06-2014
Horizon Discovery™ Group plc, the international life science company supplying research tools to organisations engaged in genomics research and the d... |
| 02.06.2014 | Horizon completes acquisition of CombinatoRx service business and assets from Zalicus Inc. | Horizon completes acquisition of CombinatoRx service business and assets from Zalicus Inc.
02-06-2014
The acquisition of a revenue generating and complementary business establishes Horizon’s headquarters in North America.
Cambridge, UK and ... |
| 15.05.2014 | Horizon Discovery Group plc to acquire CombinatoRx service business from Zalicus Inc. | Horizon Discovery Group plc to acquire CombinatoRx service business from Zalicus Inc.
15-05-2014
In a deal worth nearly £5 milllion, Horizon Discovery Group plc today announced it has agreed to acquire the CombinatoRx service business (know... |
| 07.04.2014 | Horizon Discovery launches new gene editing tools and services | Horizon Discovery™ Group plc (LSE: HZD), the life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines, today announced the launch of its full range of GENASSIS... |
| 07.04.2014 | Horizon Discovery launches new gene editing tools and services | Horizon Discovery launches new gene editing tools and services
07-04-2014
Horizon Discovery™ Group plc (LSE: HZD), the life science company supplying research tools to organisations engaged in genomics research and the development of person... |
| 24.03.2014 | Horizon Discovery Group plc raises £68.6 million | Horizon Discovery Group plc raises £68.6 million
24-03-2014
Horizon Discovery Group plc, the revenue generating life science company supplying research tools to organisations engaged in genomics research and the development of personalised ... |
| 18.02.2014 | Horizon Discovery signs supply and distribution agreement with Sirion Biotech GmbH | Horizon Discovery signs supply and distribution agreement with Sirion Biotech GmbH
18-02-2014
Horizon Discovery™, a leading provider of research tools to support translational genomics and the development of personalized medicines, announce... |
| 12.02.2014 | Horizon Discovery signs distribution agreement with Haplogen | Horizon Discovery signs distribution agreement with Haplogen
12-02-2014
Horizon will market and distribute haploid gene trap mutant collection to its global customer base.
Horizon Discovery™, a leading provider of research tools to support ... |
| 10.02.2014 | Horizon Discovery launches kits and reagents for gene-editing | Horizon Discovery launches kits and reagents for gene-editing
10-02-2014
Horizon Discovery™, a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced it has launch... |
| 10.02.2014 | Horizon Discovery launches kits and reagents for gene-editing | Horizon Discovery™, a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced it has launched the first products and services from its new GENASSIST™ range of gene ... |
| 07.01.2014 | Horizon Discovery announces new oncology research and collaboration with AstraZeneca | Horizon Discovery and AstraZeneca have entered into a research, collaboration and licence agreement to explore a range of oncology-relevant genotypes with the aim of identifying and validating a number of novel drug targets.
This deal is th... |
| 07.01.2014 | Horizon Discovery announces new oncology research and collaboration with AstraZeneca | Horizon Discovery announces new oncology research and collaboration with AstraZeneca
07-01-2014
Horizon Discovery and AstraZeneca have entered into a research, collaboration and licence agreement to explore a range of oncology-relevant geno... |
| 22.11.2013 | Horizon Discovery and AstraZeneca win “Licensing Deal of the Year” at Scrip Awards 2013 | CAMBRIDGE–(BUSINESS WIRE)–November 22, 2013–
Horizon Discovery (Horizon) has won “Licensing Deal of the Year” at the Scrip Awards 2013, for their agreement with AstraZeneca to explore Horizon’s first-in-class kinase target program HD-001 as... |
| 23.10.2013 | David Evans steps down as Chairman of the Board for Horizon Discovery | David Evans steps down as Chairman of the Board for Horizon Discovery
23-10-2013
Horizon Discovery, a leading provider of research tools to support the development of personalised medicines, today announced Mr David Evans has stepped down a... |
| 15.10.2013 | Horizon Discovery receives share of €5.75M ($7.8M) EU FP7 grant | Horizon Discovery receives share of €5.75M ($7.8M) EU FP7 grant
15-10-2013
Horizon Discovery, a leading provider of research tools to support the development of personalised medicines, today announced it has received a share of an EU FP7 Gr... |
| 15.10.2013 | Horizon Discovery receives share of €5.75M ($7.8M) EU FP7 grant | Horizon Discovery, a leading provider of research tools to support the development of personalised medicines, today announced it has received a share of an EU FP7 Grant totaling €5.75M ($7.8M), awarded to a consortium of research institutio... |
| 08.10.2013 | Horizon Discovery and Blueprint Medicines enter oncology research service agreement | Horizon Discovery and Blueprint Medicines enter oncology research service agreement
08-10-2013
Horizon Discovery, a leading provider of research tools to support the development of personalized medicines, today announced it has signed a res... |
| 16.09.2013 | Horizon Discovery licenses CRISPR gene editing technology from Harvard University | Horizon Discovery licenses CRISPR gene editing technology from Harvard University
16-09-2013
Horizon Discovery, a leading provider of research tools to support translational genomics research and the development of personalised medicines, a... |
| 03.09.2013 | Inspiring the next wave of bio innovation | Inspiring the next wave of bio innovation
03-09-2013
The forthcoming 'Beating the odds in biobusiness’ conference gains sponsorship from big pharma to inspire and encourage young and emerging biobusinesses.
Conference partners Miranda Westo... |
| 03.06.2013 | Horizon Discovery announces £6.9 million Series C continuation fundraising | Horizon Discovery, a leading provider of research tools to support the development of personalized medicines, today announced the final closing of its Series C funding round. The latest £6.9m ($10.5m) placement for ordinary shares brings to... |
| 03.06.2013 | Horizon Discovery announces £6.9 million Series C continuation fundraising | Horizon Discovery announces £6.9 million Series C continuation fundraising
03-06-2013
Horizon Discovery, a leading provider of research tools to support the development of personalized medicines, today announced the final closing of its Ser... |
| 22.04.2013 | Horizon Discovery announces >$75M oncology drug discovery collaboration with AstraZeneca | Horizon Discovery and AstraZeneca have entered into an exclusive collaboration and licence agreement to explore Horizon’s first-in-class kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types.
Th... |
| 22.04.2013 | Horizon Discovery announces >$75M oncology drug discovery collaboration with AstraZeneca | Horizon Discovery announces >$75M oncology drug discovery collaboration with AstraZeneca
22-04-2013
Horizon Discovery and AstraZeneca have entered into an exclusive collaboration and licence agreement to explore Horizon’s first-in-class ... |
| 03.04.2013 | Crown Bioscience Inc. and Horizon Discovery announce exclusive two year agreement... | Crown Bioscience Inc. and Horizon Discovery announce exclusive two year agreement...
03-04-2013
Crown Bioscience Inc. and Horizon Discovery announce exclusive two year agreement to
offer combined solutions for in vivo drug discovery model d... |
| 14.01.2013 | Horizon Discovery and Boehringer Ingelheim enter oncology research service collaboration | Horizon Discovery and Boehringer Ingelheim enter oncology research service collaboration
14-01-2013
Horizon Discovery Ltd, a leading provider of research tools to support the development of personalized medicines, today announced it has sig... |
| 08.01.2013 | Zyme and KISS collaborate to redevelop website for Horizon Discovery | Zyme and KISS collaborate to redevelop website for Horizon Discovery
08-01-2013
Life science PR and marketing agency, Zyme Communications has collaborated with KISS to redevelop the Horizon Discovery corporate website. The recently launched... |
| 16.11.2012 | Horizon Discovery launches new website | Horizon Discovery launches new website
16-11-2012
Horizon Discovery Ltd, a leading provider of research tools to support the development of personalized medicines, has launched a new, redesigned website.
The new site at www.horizondiscovery... |
| 16.11.2012 | Horizon Discovery launches new website | Horizon Discovery Ltd, a leading provider of research tools to support the development of personalized medicines, has launched a new, redesigned website.
The new site at www.horizondiscovery.com features enhanced content, including customer... |
| 13.11.2012 | Horizon Discovery and Promega launch suite of X-MAN reporter kits | Horizon Discovery and Promega launch suite of X-MAN reporter kits
13-11-2012
Horizon Discovery Ltd., a leading provider of research tools to support the development of personalied medicines, and Promega Corporation have announced the launch... |
| 06.11.2012 | Crown Bioscience, Inc. and Horizon Discovery at EORTC-NCI-AACR Symposium | Crown Bioscience, Inc. and Horizon Discovery at EORTC-NCI-AACR Symposium
06-11-2012
Santa Clara, CA and Cambridge, UK – Crown Bioscience, Inc., a leading global drug discovery and development service company, and Horizon Discovery Ltd., a l... |
| 06.08.2012 | Horizon Discovery and Domainex Ltd collaborate to support lead optimization oncology program | Horizon Discovery and Domainex Ltd collaborate to support lead optimization oncology program
06-08-2012
Horizon Discovery Ltd, a leading provider of research tools to support the development of personalised medicines, today announced it has... |
| 31.07.2012 | Horizon Discovery appoints Richard Vellacott as Chief Financial Officer | Horizon Discovery appoints Richard Vellacott as Chief Financial Officer
31-07-2012
Horizon Discovery Limited, a leading provider of research tools to support the development of personalised medicines, has announced the appointment of Mr. Ri... |
| 25.07.2012 | Horizon Discovery collaborates with NIH Center for Regenerative Medicine | Horizon Discovery collaborates with NIH Center for Regenerative Medicine
25-07-2012
Horizon Discovery, a leading provider of research tools to support the development of personalized medicines, today announced that it has signed a technolog... |
